Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery

NCT04877756 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertrophic Scar

Interventions

DRUG: OLX10010

Sponsor

Olix Pharmaceuticals, Inc.

Collaborators

[object Object]